Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07573592Not ApplicableCompleted

Clinical Evaluation of an Atopic Skin Product Containing Picea Abies Resin Extract

Role: lead

NCT06810856Not ApplicableCompleted

HRIPT Study to Evaluate the Irritation and Allergenic Potential of Medical-grade Norway Spruce (Picea Abies) Resin Salve (Abilar)

Role: lead

NCT01851590Phase 4Completed

Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis

Role: collaborator

NCT02169167Not ApplicableCompleted

Comparison of Resin Salve and Octenidine in Patients With Neuropathic Diabetic Foot Ulcers

Role: collaborator

All 4 trials loaded